rs6017340 — HNF4A HNF4A Regulatory Variant

HNF4A and the Liver's Bile Acid Thermostat

The liver performs hundreds of metabolic tasks simultaneously, and one of the most consequential is converting cholesterol into bile acids — detergent-like molecules that emulsify dietary fat and carry metabolic waste out of the body. This process is tightly regulated, because too little bile acid impairs digestion and too much accumulates to toxic levels in hepatocytes. The transcription factor HNF4A (hepatocyte nuclear factor 4 alpha)¹¹ HNF4A (hepatocyte nuclear factor 4 alpha)
A nuclear receptor expressed in liver, pancreas, kidney, and intestine; controls expression of genes involved in glucose metabolism, lipid transport, bile acid synthesis, and drug metabolism sits at the center of this regulation as one of the primary transcriptional activators of the bile acid synthesis pathway.

rs6017340 is an intronic variant within the HNF4A gene on chromosome 20 that functions as a tag SNP — a marker in linkage disequilibrium with nearby functional variants that influence HNF4A expression or regulatory activity. Alone, an intronic variant does not alter protein sequence; its significance comes from what nearby variants it represents in a given haplotype block. The C allele at this position tags haplotypes that, in at least one cohort study, were associated with faster progression of a cholestatic liver disease driven by bile acid accumulation.

The Mechanism

HNF4A acts as a master transcriptional activator of CYP7A1²² CYP7A1
Cholesterol 7alpha-hydroxylase — the rate-limiting enzyme converting hepatic cholesterol to primary bile acids; accounts for ~50% of total daily cholesterol disposal in humans (cholesterol 7alpha-hydroxylase), the rate-limiting enzyme of the classic bile acid synthesis pathway. When HNF4A binds to the CYP7A1 promoter, it activates transcription and ramps up bile acid production. Experimental studies confirm that reducing HNF4A occupancy at the CYP7A1 promoter — whether through glucagon-mediated phosphorylation³³ glucagon-mediated phosphorylation
Song & Chiang 2006 — glucagon-cAMP pathway phosphorylates HNF4alpha, reducing its promoter binding and suppressing CYP7A1 transcription or through upstream transcriptional regulators — directly lowers bile acid output. Conversely, higher HNF4A activity means more CYP7A1, more bile acid synthesis, and higher hepatic bile acid flux.

Haplotypes tagged by the C allele at rs6017340 are proposed to influence this regulatory equilibrium. If C-tagging haplotypes are associated with elevated HNF4A activity in liver tissue, the result would be greater CYP7A1-driven bile acid production. In individuals with intact bile acid clearance, this excess is excreted harmlessly. But in patients with cholestatic conditions — where bile cannot be efficiently cleared — higher bile acid synthesis rates translate directly into greater hepatocyte accumulation and accelerated liver injury.

The Evidence

The sole direct association study for rs6017340 is Inamine et al. 2013⁴⁴ Inamine et al. 2013
Inamine T et al. Association of genes involved in bile acid synthesis with the progression of primary biliary cirrhosis in Japanese patients. J Gastroenterol, 2013, which analyzed 52 tag SNPs across 11 bile acid synthesis genes in 315 Japanese patients with primary biliary cholangitis (PBC). Two HNF4A tag SNPs — rs6017340 and rs6031587 — showed significant association with disease progression. The proposed mechanism is that genetic variants activating HNF4A's role in CYP7A1 transcription elevate bile acid synthesis, worsening hepatocyte bile acid accumulation in the context of impaired biliary excretion.

This is a small, single-cohort study in an ethnically specific population, and the rsid does not appear in the GWAS Catalog and carries no ClinVar annotation. The evidence is classified as emerging — the biological mechanism is well-supported by independent literature, but the specific genetic association has not been replicated in larger studies. It is possible that rs6017340 is tagging a different causal variant that shows stronger association in Japanese populations (where the C allele reaches ~82% frequency vs ~45% in Europeans).

In the broader HNF4A context, the gene is well-established as a susceptibility locus for MODY1 (maturity-onset diabetes of the young type 1)⁵⁵ MODY1 (maturity-onset diabetes of the young type 1)
An autosomal dominant form of monogenic diabetes caused by loss-of-function HNF4A mutations; presents typically before age 25, initially responsive to sulfonylureas through rare coding mutations, and population-level HNF4A haplotypes have been associated with type 2 diabetes risk, insulin secretion, and hepatic lipid metabolism in GWAS. The rs6017340 variant is specifically associated with bile acid synthesis regulation rather than glucose homeostasis, representing a distinct functional arm of HNF4A's broad hepatic regulatory role.

Practical Implications

For carriers of the C allele, the actionable implications are confined to liver health monitoring rather than active dietary intervention. The emerging evidence links this variant specifically to progression risk in cholestatic liver disease — a condition where bile flow is impaired — rather than to general metabolic risk. Most C allele carriers will never develop PBC, which affects roughly 1 in 1,000 women (with a strong female predominance) and has a complex multifactorial etiology requiring both genetic predisposition and environmental or immunological triggers.

The most clinically useful response to the C allele is awareness of cholestatic liver disease symptoms — persistent itching (pruritus), fatigue, and right upper quadrant discomfort — and appropriate use of standard liver function testing. Ursodeoxycholic acid (UDCA), which competitively replaces more toxic bile acids and reduces CYP7A1 expression via FXR activation, is the established treatment for PBC and directly addresses the bile acid overproduction mechanism implicated by this variant.

Interactions

Within HNF4A, rs6017340 acts as a haplotype tag alongside rs6031587, and both variants were identified together in the PBC progression study. Compound heterozygosity or homozygosity at the full haplotype block likely produces stronger effects than either tag SNP captures individually.

Pathway partners include CYP7A1 variants (rs3808607 and rs3824260), which directly alter CYP7A1 promoter activity and interact with HNF4A-driven transcription. Individuals carrying both HNF4A C-tagging haplotypes and CYP7A1 promoter risk alleles may face additive upregulation of bile acid synthesis through both the transcription factor and the target gene. PPARGC1A variants were also co-identified in the same bile acid synthesis study, as PPARGC1A is an HNF4A coactivator that amplifies transcriptional output.